MdxHealth's MGMT test (Predict MDx for Brain), used to determine MGMT gene methylation status and molecular risk classification, has demonstrated success in personalizing brain cancer treatment in a major international Phase III study (RTOG 0525) of temozolomide.
The RTOG 0525 study was designed as a randomized, international phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) patients.
The investigators studied whether a continuous dose of temozolomide is effective than standard therapy.
PredictMDx for Brain is a test for predicting patient response to alkylating agents, a class of chemotherapy drugs.
The test assesses the methylation status of the MGMT gene which produces MGMT (O6-methylguanine-DNA methyl transferase), a DNA repair enzyme.
The patented DNA methylation gene test is useful for new brain cancer drug developers to target their new drugs to the patients who do not respond to the traditional alkylating agent drug regime.